Last Updated: November 16, 2026

Details for Patent: 9,956,205

« Back to Dashboard


Summary for Patent: 9,956,205
Title:Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof
Abstract:Crystalline polymorph forms of 2-(5-bromo-4-(4-cyclopropyl naphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid are described. Pharmaceutical compositions and the uses of such compounds, compound forms, and compositions for the treatment of a variety of diseases and conditions are also presented.
Inventor(s):Laszlo R. Treiber, Irina Zamansky, Jean-Luc Girardet
Assignee: Ardea Biociences Inc
Application Number:US15/150,053
Patent Claim Types:
see list of patent claims
Use;
Patent landscape, scope, and claims:

US Patent 9,956,205: Lesinurad Crystalline Polymorph Claims, Expiration, Orange Book Status, and Generic Risk

US Patent 9,956,205 protects two crystalline polymorphs of lesinurad, the active ingredient in Zurampic. Its enforceable value is concentrated in solid-state form and treatment-method claims, not in the lesinurad chemical composition itself. The patent issued May 1, 2018, and has an expected expiration date of October 30, 2035, subject to any patent-term adjustment or disclaimer recorded in the official patent file.[1]

The claims cover administration of lesinurad polymorphs identified by specific X-ray powder diffraction, or XRPD, peaks. The patent does not claim every lesinurad crystal form, every lesinurad formulation, or lesinurad as a chemical entity. Generic entry risk therefore depends on the solid form used in the ANDA product, the proposed labeling, and whether the product would be used for the patented gout indication.

What drug and crystalline forms does US Patent 9,956,205 protect?

The patent covers lesinurad, chemically identified as:

2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid.

Lesinurad is a selective uric acid transporter 1 inhibitor. The FDA approved it under the brand name Zurampic as an adjunct to a xanthine oxidase inhibitor, such as allopurinol or febuxostat, for hyperuricemia associated with gout.[2]

The patent claims two solid forms:

Patent claim group Defining XRPD peaks Additional limitations
Claims 1-6 10.46, 18.76 and 19.83° 2θ ±0.1° Optional peaks at 18.21 or 23.08°; FIG. 5 pattern; water/ethyl acetate crystallization; combination with allopurinol or febuxostat
Claims 7-12 10.32, 18.84 and 20.75° 2θ ±0.1° At least two additional peaks from the listed set; FIG. 1 pattern; water/acetic acid crystallization; combination with allopurinol or febuxostat

The claim structure indicates that the patent distinguishes at least two lesinurad polymorphs based on their diffraction signatures. The precise polymorph names, such as Form I or Form II, should not be inferred solely from the claim text unless confirmed by the specification and prosecution history.

How broad are the independent claims in US 9,956,205?

Claims 1 and 7 are method-of-treatment claims. Each requires four principal elements:

  1. Treatment of hyperuricemia associated with gout.
  2. Administration of an effective amount of lesinurad.
  3. Use of a specified crystalline polymorph.
  4. Identification of that polymorph through required XRPD peaks.

The claims do not require that the patient previously failed allopurinol or febuxostat. Claims 5, 6, 11 and 12 separately add co-administration with allopurinol or febuxostat.

The independent claims are narrower than a claim to lesinurad generally. A product could contain lesinurad yet avoid literal infringement if it uses a different crystalline form that does not satisfy the required XRPD limitations. That distinction is central to generic design-around analysis.

What do the XRPD limitations require?

The peak limitations are quantitative identity limitations. A polymorph must exhibit the specified peaks within ±0.1° 2θ. The dependent claims add either additional peak requirements or a pattern substantially the same as the patent figures.

The principal claim-construction issues are likely to include:

  • Whether each listed peak must be present in the accused material.
  • How peak position, intensity and analytical tolerance are measured.
  • The meaning of “substantially the same” XRPD pattern.
  • Whether mixtures of polymorphs fall within the claims.
  • Whether manufacturing or storage conditions convert one lesinurad form into another.
  • Whether the claimed peaks distinguish a discrete polymorph or overlap with a partially crystalline mixture.

A generic manufacturer would normally characterize the final active pharmaceutical ingredient, formulation and stability samples by XRPD. Solid-form conversion during milling, granulation, compression, storage or dissolution could create additional infringement exposure even if the initial API was manufactured as a different form.

What do claims 4 and 10 add regarding manufacturing?

Claims 4 and 10 add crystallization process limitations:

  • Claim 4 requires crystallization from a mixture of water and ethyl acetate.
  • Claim 10 requires crystallization from a mixture of water and acetic acid.

These are dependent method-of-treatment claims, not standalone manufacturing claims. The claims therefore do not directly prohibit all manufacture of a polymorph using those solvents. They require administration of the resulting polymorph and incorporate the specified crystallization step into the claimed treatment method.

This structure makes claims 4 and 10 narrower and potentially harder to assert against a generic manufacturer unless the manufacturing route is discoverable and matches the claimed solvent system. The broader enforcement value remains in claims 1 and 7, which do not require the accused manufacturer to use the listed crystallization process.

What do the allopurinol and febuxostat combination claims protect?

Claims 5, 6, 11 and 12 cover administration of the claimed lesinurad polymorph with either:

  • Allopurinol; or
  • Febuxostat.

These claims align with Zurampic’s FDA-approved use as add-on therapy to a xanthine oxidase inhibitor. They could become relevant where a generic label expressly instructs concurrent use with allopurinol or febuxostat.

The combination claims are narrower than the independent polymorph claims because they require proof of co-administration. They may still have practical value if the FDA-approved indication and prescribing information encourage use with those agents. A generic applicant seeking a Section viii carve-out would need to remove patented methods from labeling where FDA rules permit such a carve-out. Whether a carve-out is available depends on the scope of the listed use code and the remaining non-patented indications.

When does US Patent 9,956,205 expire?

Event Date
Earliest priority date reported for the family October 31, 2014
International or nonprovisional filing period October 30, 2015
US patent issuance May 1, 2018
Expected ordinary expiration October 30, 2035
Patent term adjustment Must be confirmed from the USPTO patent record
Patent term extension under 35 U.S.C. §156 No confirmed extension identified for this patent

The expected expiration is based on the 20-year term calculated from the relevant nonprovisional filing date. A provisional filing does not begin the 20-year patent term. Any patent-term adjustment shown on the front page or USPTO maintenance record could move the effective expiration date.[1]

The patent issued after FDA approval of Zurampic, which occurred on December 22, 2015. FDA approval did not create a biologic exclusivity period because lesinurad is a small-molecule drug.[2]

What is the FDA and Orange Book status of Zurampic?

Zurampic was approved by FDA as an oral lesinurad product for use with an xanthine oxidase inhibitor in patients with gout-associated hyperuricemia.[2] The approved labeling did not authorize lesinurad monotherapy because of renal safety concerns.

Key FDA facts include:

Regulatory item Status
Active ingredient Lesinurad
Brand Zurampic
Sponsor at approval AstraZeneca
FDA approval date December 22, 2015
Dosage form Oral tablet
Approved use Adjunct to allopurinol or febuxostat
Regulatory pathway NDA, small molecule
Biosimilar pathway Not applicable
Generic pathway ANDA under Hatch-Waxman
Market status US commercial availability was discontinued after limited commercial uptake

FDA’s Orange Book status must be separated from the patent’s technical scope. Orange Book listing provides notice for ANDA applicants and supports patent-certification procedures, but it does not expand claims beyond their actual language. The relevant listed patent, if active in the applicable Orange Book edition, would expose an ANDA applicant to a Paragraph IV certification and possible litigation under 35 U.S.C. §271(e)(2).

Are there Paragraph IV challenges to US 9,956,205?

A Paragraph IV challenge would assert that the patent is invalid, unenforceable or not infringed. For this patent, the most likely technical grounds would involve:

  • A different lesinurad polymorph.
  • Failure of the proposed product to exhibit the claimed XRPD peaks.
  • Lack of infringement because the label omits the patented gout-treatment use.
  • Anticipation or obviousness based on earlier lesinurad solid-form disclosures.
  • Insufficient written description or enablement for the claimed polymorph definitions.
  • Indefiniteness involving “substantially the same” XRPD patterns.
  • Non-infringement of the solvent-specific dependent claims.

The patent’s method format creates a significant Hatch-Waxman issue. An ANDA applicant can seek approval for a label that omits a patented method, but that strategy does not eliminate risk if the remaining label still induces use of the claimed polymorph for hyperuricemia associated with gout.

No major public patent-litigation campaign involving US 9,956,205 is identified in the materials supplied with the claim set. The existence of a Paragraph IV notice, settlement agreement or district-court action must be determined from the Orange Book, FDA Paragraph IV notice records and PACER litigation filings.

How strong is the patent estate for lesinurad?

US 9,956,205 is a focused solid-state patent. Its strength is strongest where the commercial product uses one of the claimed polymorphs and the product label covers the claimed gout indication.

Risk factor Assessment
Chemical composition protection Not provided by the quoted claims
Polymorph protection Strong for the two XRPD-defined forms
Formulation protection Not provided by the quoted claims
Method-of-use protection Present and tied to gout-associated hyperuricemia
Combination protection Present for allopurinol and febuxostat
Manufacturing protection Limited; solvent steps appear only in dependent treatment claims
Small-molecule generic exposure Material if the generic uses a claimed form
Biosimilar exposure None
Design-around potential Meaningful if a stable, non-infringing form can be developed
Analytical enforceability Dependent on XRPD testing and form stability

The patent does not, on the supplied claims, cover tablets, excipients, dissolution profiles, particle size, salt forms, dosage strengths, packaging or a general method of lowering serum urate. Separate patents would be needed for those features.

Which companies challenge or compete with lesinurad?

Lesinurad competes pharmacologically with established urate-lowering therapies:

Product Active ingredient Mechanism or role Generic or biosimilar status
Zurampic Lesinurad URAT1 inhibitor used with a xanthine oxidase inhibitor Small-molecule generic pathway
Zyloprim and generics Allopurinol Xanthine oxidase inhibitor Generic competition established
Uloric and generics Febuxostat Xanthine oxidase inhibitor Generic competition established
Krystexxa Pegloticase Enzyme replacement therapy Biologic; biosimilar considerations differ
Benemid and generics Probenecid Uricosuric therapy Generic competition established

Lesinurad’s commercial position was weakened by the requirement for combination use, renal safety monitoring and competition from low-cost allopurinol and febuxostat. AstraZeneca discontinued US commercial availability after limited uptake, reducing current revenue exposure relative to the period immediately after launch.[3]

What generic launch scenarios exist for Zurampic?

Three launch scenarios are commercially relevant.

At-risk launch before October 2035

A generic applicant could file an ANDA with a Paragraph IV certification and launch before patent expiration if it prevails in litigation or reaches a settlement permitting launch. The principal litigation question would be whether the API or finished product contains a claimed polymorph.

Delayed launch after a successful design-around

A manufacturer could develop a non-infringing crystalline form and support it with XRPD, thermal analysis and stability data. This route would reduce infringement risk but would require regulatory support showing that the alternative form is pharmaceutically equivalent and does not create unacceptable manufacturing or bioavailability differences.

Label carve-out

A generic applicant could attempt to remove patented combination-use language. This strategy is less useful if the only commercially meaningful use is the patented adjunctive gout indication. FDA labeling, use codes and actual prescribing behavior would control practical exposure.

Because the product was commercially discontinued, the incentive to file an ANDA may be lower than for a high-revenue branded drug. Low current sales do not eliminate patent risk, but they reduce the expected value of an expensive polymorph challenge.

What licensing deals affect the lesinurad patent landscape?

AstraZeneca acquired Ardea Biosciences in 2012 and obtained control of Ardea’s lesinurad program and related intellectual property.[4] That transaction consolidated ownership of the lesinurad patent estate under AstraZeneca. The relevant commercial rights and licensing arrangements should be distinguished from patent ownership: a company may commercialize or distribute a product without owning the underlying patent.

The supplied patent claims identify the patent holder and inventorship through the official patent record, but they do not establish a separate license grant, covenant not to sue or generic settlement. No such agreement can be inferred from the claims alone.

Key Takeaways

  • US Patent 9,956,205 is a lesinurad crystalline-polymorph patent.
  • Claims 1 and 7 cover treatment of gout-associated hyperuricemia using two XRPD-defined polymorphs.
  • Claims 5, 6, 11 and 12 cover combination use with allopurinol or febuxostat.
  • Claims 4 and 10 add water/ethyl acetate and water/acetic acid crystallization limitations.
  • The expected patent expiration is October 30, 2035, subject to USPTO-recorded term adjustments.
  • The patent does not, based on the supplied claims, cover the lesinurad molecule broadly, tablets generally or every lesinurad solid form.
  • Generic risk is highest when the proposed product contains either claimed polymorph and carries the approved gout-treatment labeling.
  • Lesinurad is a small molecule, so biosimilar competition is not applicable.
  • The commercial incentive for a Paragraph IV challenge is reduced by Zurampic’s limited US commercial performance and discontinuation.

FAQs

Does US Patent 9,956,205 cover lesinurad monotherapy?

No. The quoted claims require treatment of hyperuricemia associated with gout using a specified lesinurad crystalline polymorph. Claims 5, 6, 11 and 12 specifically require combination with allopurinol or febuxostat, consistent with Zurampic’s adjunctive FDA label.

Can a generic use a different lesinurad polymorph?

Potentially. A different polymorph may avoid literal infringement if it does not meet the claimed XRPD peak limitations. The generic manufacturer would need analytical data demonstrating that the product does not convert into a claimed form during manufacturing, storage or use.

Is US Patent 9,956,205 a formulation patent?

No. The quoted claims are directed to crystalline forms and treatment methods. They do not recite tablet excipients, coatings, dissolution characteristics, dosage strengths or a specific finished dosage-form composition.

Does the patent protect crystallization using water and ethyl acetate?

Only in the narrow context of dependent claim 4. The quoted claim does not independently prohibit manufacturing with water and ethyl acetate. It requires administration of the resulting polymorph in the claimed treatment method.

Is a biosimilar filing available for Zurampic?

No. Lesinurad is a small-molecule active ingredient regulated through the NDA/ANDA framework. A competing manufacturer would pursue a generic drug application rather than a biosimilar application.

References

  1. United States Patent and Trademark Office. (2018). U.S. Patent No. 9,956,205, Crystalline forms of lesinurad.
  2. U.S. Food and Drug Administration. (2015). Zurampic (lesinurad) prescribing information and approval materials.
  3. AstraZeneca PLC. (2019). Annual report and product portfolio disclosures.
  4. AstraZeneca PLC. (2012). Acquisition of Ardea Biosciences and lesinurad program materials.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 9,956,205

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ironwood Pharms Inc DUZALLO allopurinol; lesinurad TABLET;ORAL 209203-001 Aug 18, 2017 DISCN Yes No 9,956,205 ⤷  Start Trial TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE ⤷  Start Trial
Ironwood Pharms Inc DUZALLO allopurinol; lesinurad TABLET;ORAL 209203-002 Aug 18, 2017 DISCN Yes No 9,956,205 ⤷  Start Trial TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE ⤷  Start Trial
Ironwood Pharms Inc ZURAMPIC lesinurad TABLET;ORAL 207988-001 Dec 22, 2015 DISCN Yes No 9,956,205 ⤷  Start Trial TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A XANTHINE OXIDASE INHIBITOR ALONE ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,956,205

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 084639 ⤷  Start Trial
Australia 2011352129 ⤷  Start Trial
Brazil 112013016982 ⤷  Start Trial
Canada 2817249 ⤷  Start Trial
China 103298796 ⤷  Start Trial
Cyprus 1118621 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.